Our name derives from The WORD “mandala”, an ancient circular symbol of wholeness, unity, and health. 

Artboard 3 copy.png

MandalMed is a privately-held company focused on modulation of glycobiology and innate immunity to develop treatments for organ fibrosis. The initial target is galectin-3, one of a family of carbohydrate binding proteins. The lead product is MM-003, a protein inhibitor of galectin-3, for prevention and reversal of fibrosis after myocardial infarction and in heart failure.